AOD-9604
Men's HealthFor men using AOD-9604 in andropause, performance, or recovery contexts, the operating concerns are hormonal coherence, cardiovascular safety, and integration with the broader male-endocrine stack. The compound is delivered at 300-500 mcg 1x daily am via subq/oral (capsule, lower bioavailability) with monitoring centred on the HPG panel. The mechanistic basis is mimics the c-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the gh receptor or driving igf-1 elevation, with downstream effects examined below.
Key Takeaways
Male-physiology lens: AOD-9604 is evaluated against HPG-axis interaction, TRT compatibility, and prostate / cardiovascular considerations. Mechanism: Mimics the C-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the GH receptor or driving IGF-1 elevation. Male monitoring: baseline testosterone (total/free), LH, FSH, estradiol, prolactin, SHBG; 6-8 week follow-up panel. Male dose: 300-500 mcg 1x daily am via subq/oral (capsule, lower bioavailability); cycle 8-12 weeks. Male-physiology stack partners: Kisspeptin, Gonadorelin (GnRH), PT-141.
Mimics the C-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the GH receptor or driving IGF-1 elevation. The male-physiology question is how this mechanism interacts with the HPG axis, with exogenous testosterone or HCG-paired protocols, and with prostate, hematocrit, and cardiovascular indices. The subsections below address HPG-axis interaction, TRT compatibility, body composition response, and prostate considerations for AOD-9604.
Male body composition and performance response
Male users typically respond to AOD-9604 on the recovery, lean-mass, or visceral-fat dimension depending on the compound's primary pharmacology. Mimics the C-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the GH receptor or driving IGF-1 elevation. For men whose body composition goals are driven by training, the dose-timing relative to workouts and sleep is often the critical lever rather than the absolute dose itself.
Sexual function and prostate considerations
Where AOD-9604 alters circulating LH, testosterone, or local androgen signalling, prostate considerations become relevant for men over 40. Baseline PSA, periodic re-check, and avoidance of stacking that compounds androgenic load are all reasonable precautions. For molecules whose effects are predominantly outside the HPG axis, the prostate consideration is largely background.
Compatibility with TRT and post-cycle protocols
For men currently on TRT or planning a post-cycle restart, AOD-9604 is typically compatible because it operates on a separate (somatotrophic) axis. The dominant interaction to watch for is on the metabolic and recovery layers rather than the hormonal layer. Where the molecule's pharmacology overlaps with HCG, gonadorelin, or kisspeptin, dose layering is the standard approach.
For fat loss (male) in male users, AOD-9604 is most-effective when paired with comprehensive labs (testosterone total/free, LH, FSH, estradiol sensitive, prolactin, SHBG) at baseline and follow-up. Cycle length 8–12 weeks with re-evaluation.
Where male users target andropause, AOD-9604 is typically integrated with the broader hormonal protocol — TRT, kisspeptin, gonadorelin, or HCG — rather than used in isolation. The integration approach varies by clinic.
HPG Axis Support in men responds to AOD-9604 with effect sizes that vary substantially by baseline status — men with documented suboptimal status respond more strongly than those at the upper end of normal. The protocol pattern in clinical use reflects this.
For libido in male users, AOD-9604 is most-effective when paired with comprehensive labs (testosterone total/free, LH, FSH, estradiol sensitive, prolactin, SHBG) at baseline and follow-up. Cycle length 8–12 weeks with re-evaluation.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 300-500 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 180-500 mcg | 4–6 weeks initial cycle |
| Men's Health focus | SubQ | 300-500 mcg | 1x daily AM |
| Maintenance phase | SubQ | 210-500 mcg | Ongoing with periodic pauses |
Dose timing for AOD-9604 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.
AOD-9604 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from men's-health clinicians.
- AOD-9604 + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with AOD-9604's mechanism in male physiology protocols.
- AOD-9604 + Gonadorelin (GnRH): Binds the GnRH receptor on anterior pituitary gonadotrophs in a pulsatile fashion to stimulate LH (and to a lesser extent FSH) release. Pairs naturally with AOD-9604's mechanism in male physiology protocols.
- AOD-9604 + PT-141: Activates MC4R in the hypothalamus and other CNS regions involved in sexual response. Pairs naturally with AOD-9604's mechanism in male physiology protocols.
- AOD-9604 + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with AOD-9604's mechanism in male physiology protocols.
No significant elevation of IGF-1, glucose, or insulin in trials. Generally well tolerated. Pregnancy/lactation: avoid (no data).
Lens-specific safety considerations for male physiology use of AOD-9604: No significant elevation of IGF-1, glucose, or insulin in trials. Generally well tolerated. Pregnancy/lactation: avoid (no data). Additional male physiology monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| AOD-9604 | GH fragment | ~30 min IV; longer SubQ | Men's Health |
| Kisspeptin | Hypothalamic upstream regulator of GnRH | ~28 min IV | The upstream master regulator of GnRH neurons — driving the entire HPG axis from above |
| Gonadorelin (GnRH) | Hypothalamic decapeptide | ~2-4 min | The natural decapeptide that drives pituitary release of LH and FSH — used clinically and increasingly as an HCG alternative during testosterone therapy |
| PT-141 | Melanocortin receptor agonist | ~2-3 hr | An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women |
How does AOD-9604 affect the HPG axis?
Does AOD-9604 affect hair, prostate, or erythrocyte production?
Will AOD-9604 affect fertility or sperm quality?
Is AOD-9604 compatible with TRT?
What does AOD-9604 stack well with?
What route should I use for AOD-9604?
Start a AOD-9604 Protocol
Alukard provides physician-supervised men's health protocols with GMP-certified AOD-9604 and GMP-certified compounds with comprehensive hormone panels.
Get ProtocolQuick Facts
- Molecular weight
- 1815.1 Da
- Sequence length
- 16 aa
- Half-life
- ~30 min IV; longer SubQ
- WADA
- Not on prohibited list (verify annually)
- FDA
- Unapproved (Research Only)
- Research
- Phase IIb completed; not commercialised
All male physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for AOD-9604 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Male Physiology Protocol for AOD-9604
Alukard provides physician-supervised men's health protocols with GMP-certified compounds with comprehensive hormone panels.
HIPAA Compliant · GMP Certified · Physician Supervised